Insider Transactions in Q1 2025 at Immunity Bio, Inc. (IBRX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2025
|
Barry J. Simon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,453
-0.17%
|
$16,359
$3.42 P/Share
|
|
Feb 22
2025
|
Barry J. Simon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,243
+0.47%
|
-
|
|
Feb 22
2025
|
Richard Adcock CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
78,167
-18.95%
|
$234,501
$3.42 P/Share
|
|
Feb 22
2025
|
Richard Adcock CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
152,439
+26.98%
|
-
|
|
Feb 22
2025
|
David C. Sachs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,860
-6.57%
|
$47,580
$3.42 P/Share
|
|
Feb 22
2025
|
David C. Sachs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,650
+14.41%
|
-
|
|
Feb 22
2025
|
Patrick Soon Shiong Director |
SELL
Payment of exercise price or tax liability
|
Direct |
42,071
-0.14%
|
$126,213
$3.42 P/Share
|
|
Feb 22
2025
|
Patrick Soon Shiong Director |
BUY
Exercise of conversion of derivative security
|
Direct |
114,329
+0.38%
|
-
|
|
Feb 22
2025
|
Regan J Lauer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,669
-1.49%
|
$5,007
$3.42 P/Share
|
|
Feb 22
2025
|
Regan J Lauer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,065
+3.5%
|
-
|
|
Jan 22
2025
|
Barry J. Simon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
110,020
+3.29%
|
$220,040
$2.0 P/Share
|